As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
HOME > ORGANIZATION
ORGANIZATION
- JPMA Gearing Up for Drug Pricing Reform Debate towards December: Exec
November 17, 2023
- Policy Veterans’ Group Renews Call for Company-Proposed Pricing, Floats Support System for Biosimilars
November 15, 2023
- PhRMA Chief Presses Japan to Cut LLP Spending, Shift Funds towards Innovation
November 15, 2023
- PhRMA Chair Urges Japan to Maintain On-Patent Drug Prices, Improve Initial Pricing
November 10, 2023
- Diabetes Groups Urge Govt to Build Stable Supply System for GLP-1s, Other Meds
November 8, 2023
- Chuikyo Rep Interview 4 - JMA Rep Says Any Reform Must Ensure Access to Appropriate Healthcare
November 6, 2023
- GHIT Fund, MPP to Bolster Ties to Enhance Drug Access
October 31, 2023
- 70% of Younger Wholesaler Staffers Ponder Quitting Jobs amid Supply Crunch: Poll
October 30, 2023
- Shipments Curbed or Suspended for 22.9% of Products in September: FPMAJ
October 27, 2023
- Japan Needs New Rule to Price Drugs on Par with US, Europe: JPMA Director
October 27, 2023
- JMA to Seek Wage Hike of “at Least 3%” in 2024 Revision: President
October 27, 2023
- Chuikyo Rep Interview 3-2 - Rengo Wants Substantive Discussions on Pricing System, Off-Year Revisions over Next Few Years
October 26, 2023
- Off-Label Use of GLP-1 Goes against Medical Ethics: JMA Executive
October 26, 2023
- Chuikyo Rep Interview 3-1 - Rengo Seeks Patient-Centric Debate, Sees Exhausted Wholesalers as Big Issue
October 25, 2023
- Neurology Society, SMA Group Urge Nationwide Newborn Test at Public Expense
October 20, 2023
- No Info Received from Member Firms on Impact of Middle East Crisis: JPMA
October 20, 2023
- JGA Vows Cooperation after Generic Panel’s Interim Report
October 20, 2023
- JPMA Renews Call for Abolishing PMP Company Criteria
October 20, 2023
- Group of Academia-Originating Biotechs Boots Up in Japan
October 18, 2023
- Introduce Societal Value Premium for Regenerative Medicine Products: Consultant
October 17, 2023
ページ
A total of 43 innovative new medicines are anticipated to be approved or listed in Japan this year, according to a survey by Jiho. At the center of attention are some highly innovative, but probably ultra-expensive, gene therapies, as well…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…